載入...
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Specific DNA a...
Na minha lista:
| 發表在: | NPJ Precis Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8213828/ https://ncbi.nlm.nih.gov/pubmed/34145376 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00199-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|